{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016267","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.302285+00:00","generated_at":"2026-06-15T04:55:15.506065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024","bullets":["R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.","Cash and equivalents $21.7M at March 31, 2023, down from $26.4M at Dec 31, 2022; cash runway into Q2 2024.","First patient dosed in Phase 1 trial of Decoy20 for solid tumors in March 2023; three trial sites activated.","Patent allowances in Brazil and India bring IP protection to 32 countries for Decoy platform.","Robert Martell, M.D., Ph.D. elected to Board of Directors in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016267","json":"https://secwatch.observer/filing/0001493152-23-016267.json","markdown":"https://secwatch.observer/filing/0001493152-23-016267.md","text":"https://secwatch.observer/filing/0001493152-23-016267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/0001493152-23-016267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:55:15.506065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ed0788c7e82492279fc0b055c6c61f2ffd8f09a","claim":"Indaptus Therapeutics, Inc. reported first quarter ended March 31, 2023 results: EPS approximately $0.51.","evidence_excerpt":"Loss per share for the three-month period ended March 31, 2023 was approximately $0.51 compared with approximately $0.41 for the three-month period ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223016267/0001493152-23-016267-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"EPS","value":"approximately $0.51"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}